熱門資訊> 正文
Instil Bio非GAAP每股收益为-3.24美元
2025-08-13 20:37
- Instil Bio press release (NASDAQ:TIL): Q2 Non-GAAP EPS of -$3.24.
- As of June 30, 2025, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of $103.6 million, which consisted of $7.7 million in cash and cash equivalents, approximately $0.2 million in restricted cash, $84.1 million in marketable securities, and $11.7 million in long-term investments, compared to $115.1 million in cash,
More on Instil Bio
- Instil Bio: Chasing After Summit And BioNTech, Albeit With Some Hiccups
- Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates
- Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success
- Instil Bio to begin testing antibody therapy in solid tumors
- Instil Bio appoints Jamie Freedman as Chief Medical Officer
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
